Does Cosentyx Cause Liver Damage?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, does not commonly affect liver function. Clinical trials and post-marketing data show no direct hepatotoxicity or elevated liver enzymes as a frequent adverse event. Liver-related issues occur in less than 1% of patients, often linked to underlying conditions or concurrent medications rather than the drug itself.[1][2]
What Do Clinical Studies Show on Liver Enzymes?
In pivotal trials like FUTURE 1-5 for psoriatic arthritis and MEASURE for ankylosing spondylitis, alanine aminotransferase (ALT) elevations above three times the upper limit of normal were rare (0.1-0.5% incidence), with no cases leading to discontinuation due to liver injury. Aspartate aminotransferase (AST) changes followed similar patterns. No signals of drug-induced liver injury (DILI) emerged in over 20,000 patient-years of exposure.[3][4]
What Happens If You Have Pre-Existing Liver Disease?
No specific contraindications exist for mild liver impairment, but data is limited in severe cases (Child-Pugh C). Novartis recommends monitoring liver enzymes before and during treatment if risk factors like viral hepatitis or alcohol use are present. In patients with hepatitis B or C, reactivation risk is low compared to TNF inhibitors, but screening is advised.[2][5]
How Does It Compare to Other Biologics on Liver Safety?
Unlike methotrexate (which causes 15-20% ALT elevations) or TNF blockers (1-3% serious liver events), Cosentyx has a cleaner liver profile. Head-to-head data is sparse, but real-world registries like CorEvitas report fewer hepatic adverse events with IL-17 inhibitors versus JAK inhibitors or older DMARDs.[6]
When Should You Monitor Liver Function?
Baseline and periodic tests (every 3-6 months) are suggested for at-risk patients, per FDA labeling. Symptoms like jaundice or fatigue warrant immediate checks, though causality is unproven in most reports.[2]
[1] Cosentyx Prescribing Information, Novartis, 2023. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
[2] FDA Label for Secukinumab, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf
[3] van de Kelft et al., Lancet (FUTURE trials), 2018. https://pubmed.ncbi.nlm.nih.gov/29336895/
[4] Baeten et al., Ann Rheum Dis (MEASURE trials), 2015. https://pubmed.ncbi.nlm.nih.gov/25897097/
[5] EULAR Recommendations for PsA, 2022. https://ard.bmj.com/content/81/9/1272
[6] CorEvitas PsA Registry data, 2023 abstract. https://acrabstracts.org/abstract/long-term-effectiveness-and-safety-of-secukinumab-in-psoriatic-arthritis-from-the-us-based-corevitas-psoriatic-arthritis-spondyloarthritis-registry/